Premium
Low‐dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T‐cell lymphoma lesions
Author(s) -
Akilov O.E.,
Grant C.,
Frye R.,
Bates S.,
Piekarz R.,
Geskin L.J.
Publication year - 2012
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2012.10905.x
Subject(s) - romidepsin , medicine , mycosis fungoides , refractory (planetary science) , radiation therapy , lymphoma , histone deacetylase inhibitor , chemotherapy , dermatology , surgery , oncology , gastroenterology , histone deacetylase , biochemistry , chemistry , gene , histone , physics , astrobiology
Summary Background Romidepsin is a structurally unique histone deacetylase inhibitor approved by the U.S. Food and Drug Administration for therapy of relapsed or refractory cutaneous T‐cell lymphoma (CTCL). Localized electron beam radiation therapy (LEBT) is standard practice in the care of patients with chronically traumatized and painful lesions. Combination therapy of those two modalities may be beneficial for the therapy of CTCL. Objectives To report observations on supportive LEBT utilized for isolated refractory lesions in patients on romidepsin. Methods Observations were made during a phase II clinical trial sponsored by the National Cancer Institute (NCI‐1312) examining the efficacy of romidepsin for patients with relapsed, refractory or advanced CTCL, stage IB–IVA mycosis fungoides (MF) or Sézary syndrome. Skin responses were assessed by evaluation of five target lesions only. Patients with objective clinical responses in target lesions who had symptomatic nontarget lesions were allowed limited LEBT to isolated lesions for symptomatic relief. Patients who received localized radiation were not considered complete responders at any point. Results Five patients with advanced MF (three stage IIB and two stage IVA2) received LEBT to symptomatic nontarget lesions while on a protocol with romidepsin. None of these patients experienced additional or unexpected toxicity. Four of the five patients demonstrated fast and durable responses. We noted that significantly lower than standard doses of LEBT effectively treated symptomatic lesions in these patients. Conclusions LEBT demonstrated significant responses at very low doses without additional toxicity in patients on protocol treatment with the histone deacetylase inhibitor romidepsin. This merits formal investigation in a clinical trial for potential synergy in patients with CTCL.